Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01993641
Title Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors MEI Pharma, Inc.
Indications

bone marrow cancer

Therapies

Pracinostat

Azacitidine

Decitabine

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.